Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05985434
Other study ID # 0009120
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 21, 2018
Est. completion date December 1, 2023

Study information

Verified date January 2024
Source Istituto Ortopedico Rizzoli
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Perspective observational cohort study in which the data relating to patients affected by one or more vertebral metastases or by vertebral localization of hemolifoproliferative malact and surgical treatment candidates will be collected, which will be recruited at the Complex Structure of Spine Surgery for Oncological and Degenerative Rizzoli Orthopedic Institute starting from the date of approval of the same study. Patients of both sexes and aged 18 years or older will be included. Patients with primary (benign or malignant) tumors of the vertebrae and patients unable to consent to the study will be excluded from the study. For each patient, in addition to the demographic data, preoperative information will be collected: type of tumor, involved vertebral levels, presence of pathological fracture, presence of visceral metastases, presence and number of other bone metastases, neurological picture according to Frankel's scale, evaluated pain according to the Visual Analogue Scale (VAS), functional status according to Karnofsky, EuroQoL-5D and SF-36 questionnaires on the quality of life; information related to the intervention itself: access, type of surgical treatment, possible preoperative embolization; intraoperative complications; information at discharge: postoperative complications, pain, neurological picture, functional status; follow-up data: pain, neurological picture, functional status, SF-36 questionnaire, late complications, local recurrence; systemic progression of the disease. Follow-up checks will be performed at 3 months, 6 months, 12 months, 18 months, 24 and 36 months. The timing of the controls and the examinations requested by the patients will be those of normal clinical practice. Primary endpoint is the change in quality of life (measured by scores EQ-5D and SF-36) and pain (measured using the VAS score) following surgery compared to pre-operative values.


Description:

STUDY DESIGN Analytical Prospective Longitudinal cohort Not checked RATIONALE OF THE STUDY The improvement of the systemic control of oncological diseases achieved in recent years has led to a considerable increase in patient survival; it was associated with a parallel increase in the onset of symptomatic vertebral metastases. Such metastases are often associated with pain, mechanical instability of the spine, and even possible neurological deficits, which negatively affect the patient's quality of life and indirectly also on his survival. The treatment of these metastases is defined by a multidisciplinary approach; surgery is indicated in the presence of mechanical instability, signs of neurological compression, intractable pain, progression of disease during systemic treatment. The indication and the type of intervention are defined following a reference algorithm (A. Gasbarrini, M. Cappuccio, L. Mirabile, S. Bandiera, S. Terzi, G. Barbanti Bròdano, S. Boriani.) Spinal Metastases: treatment evaluation algorithm Eur Eur Med Pharmacol Sci 2004; 8: 265-274), in collaboration with the team of specialists involved. Within the multidisciplinary team it is usually the Oncologist who provides an estimate of the prognosis quoad vitam, based on the general status of the patient and the residual therapeutic possibilities. The goal of surgery is the local control of the disease and the improvement of the patient's quality of life. Although there are works in the literature that demonstrate the effectiveness of surgical treatment in vertebral metastases, there are few prospective studies in which, in addition to survival, the improvement in the quality of life after the intervention is evaluated, and the improvement over time is maintained. DESCRIPTION OF THE STUDY The study is monocentric, of a prospective observational type, with a single arm. The study will collect data relating to patients affected by one or more vertebral metastases or by vertebral localization of hemolymphoproliferative disease candidates for surgical treatment, which will be recruited at the Complex Structure of Spine Surgery for Oncological and Degenerative Address of the Rizzoli Orthopedic Institute starting from date of approval of the study itself. Patients of both sexes and aged 18 years or older will be included DATA COLLECTION For each patient will be collected, in addition to demographic data: - preoperative information: type of tumor, vertebral levels involved, presence of pathological fracture, presence of visceral metastases, presence and number of other bone metastases, functional status according to Karnofsky (Annex 1), neurological picture according to Frankel's scale (Annex 2) , pain assessed according to the Visual Analogue Scale (VAS), EuroQoL-5D and SF-36 questionnaires on the quality of life; - information on the intervention: access, type of surgical treatment, possible preoperative embolization; intraoperative complications; - information at discharge: postoperative complications, pain, neurological picture, functional status; - follow-up data: pain (VAS scale), neurological picture (according to the Frankel scale), functional status according to Karnofsky, EuroQoL-5D and SF-36 questionnaires on quality of life, late complications, local recurrence; systemic progression of the disease. The clinical data necessary for the research will be extracted from the patient's medical record and from its source documents. A specific data collection form will be used to collect the clinical information and the results of the analysis foreseen by the study. For each patient included in the study, the data collection form (Case Report Form - CRF) will be compiled. Follow-up checks will be performed, as per clinical practice, at 3 months, 6 months, 12 months, 18 months, 24 months and 36 months.


Recruitment information / eligibility

Status Completed
Enrollment 191
Est. completion date December 1, 2023
Est. primary completion date December 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients who are candidates for surgery at the level of the spine at the SC of Spine Surgery, for: or vertebral metastases or or vertebral localizations from hemolymphoproliferative diseases - Patients aged = 18 years - Patients giving written informed consent to the study Exclusion Criteria: - Patients with malignant or benign vertebral tumors - Patients suffering from vertebral metastases or vertebral localizations from hemolymphoproliferative diseases for which there are no indications for surgical treatment

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Surgical treatment
decompression with or without stabilization; stabilization only; debulking; en bloc resection

Locations

Country Name City State
Italy Istituto Ortopedico Rizzoli Bologna

Sponsors (1)

Lead Sponsor Collaborator
Istituto Ortopedico Rizzoli

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain evaluation Visual Analogue Scale (VAS) patient-administered questionnaire At baseline (day 0)
Primary Pain evaluation Visual Analogue Scale (VAS) patient-administered questionnaire At 3 months follow up
Primary Pain evaluation Visual Analogue Scale (VAS) patient-administered questionnaire At 6 months follow up
Primary Pain evaluation Visual Analogue Scale (VAS) patient-administered questionnaire At 12 months follow up
Primary Pain evaluation Visual Analogue Scale (VAS) patient-administered questionnaire At 18 months follow up
Primary Pain evaluation Visual Analogue Scale (VAS) patient-administered questionnaire At 24 months follow up
Primary Pain evaluation Visual Analogue Scale (VAS) patient-administered questionnaire At 36 months follow up
Primary Quality of life evaluation EuroQoL- 5D (EQ-5D) patient-administered questionnaire At baseline (day 0)
Primary Quality of life evaluation EuroQoL- 5D (EQ-5D) patient-administered questionnaire At 3 months follow up
Primary Quality of life evaluation EuroQoL- 5D (EQ-5D) patient-administered questionnaire At 6 months follow up
Primary Quality of life evaluation EuroQoL- 5D (EQ-5D) patient-administered questionnaire At 12 months follow up
Primary Quality of life evaluation EuroQoL- 5D (EQ-5D) patient-administered questionnaire At 18 months follow up
Primary Quality of life evaluation EuroQoL- 5D (EQ-5D) patient-administered questionnaire At 24 months follow up
Primary Quality of life evaluation EuroQoL- 5D (EQ-5D) patient-administered questionnaire At 36 months follow up
Primary Health survey Short Form Health Survey 36 (SF-36) patient-administered questionnaire At baseline (day 0)
Primary Health survey Short Form Health Survey 36 (SF-36) patient-administered questionnaire At 3 months follow up
Primary Health survey Short Form Health Survey 36 (SF-36) patient-administered questionnaire At 6 months follow up
Primary Health survey Short Form Health Survey 36 (SF-36) patient-administered questionnaire At 12 months follow up
Primary Health survey Short Form Health Survey 36 (SF-36) patient-administered questionnaire At 18 months follow up
Primary Health survey Short Form Health Survey 36 (SF-36) patient-administered questionnaire At 24 months follow up
Primary Health survey Short Form Health Survey 36 (SF-36) patient-administered questionnaire At 36 months follow up
Secondary Prognostic factor- 1 Surgery-related adverse events collected by SAVES-v.2 system 3 months follow up
Secondary Prognostic factor- 2 Survival rate 3 months follow up
Secondary Prognostic factor- 1 Surgery-related adverse events collected by SAVES-v.2 system 6 months follow up
Secondary Prognostic factor- 2 Survival rate 6 months follow up
Secondary Prognostic factor- 1 Surgery-related adverse events collected by SAVES-v.2 system 12 months follow up
Secondary Prognostic factor- 2 Survival rate 12 months follow up
Secondary Prognostic factor- 1 Surgery-related adverse events collected by SAVES-v.2 system 24 months follow up
Secondary Prognostic factor- 2 Survival rate 24 months follow up
Secondary Prognostic factor- 1 Surgery-related adverse events collected by SAVES-v.2 system 36 months follow up
Secondary Prognostic factor- 2 Survival rate 36 months follow up
See also
  Status Clinical Trial Phase
Recruiting NCT00294151 - Potential Vertebroplasty Use in the Treatment of Vertebral Metastasis From Breast and Prostate Cancer Phase 3
Recruiting NCT03951493 - Multicentre Medical-economic Study Evaluating the Efficacy of Adding ZOlédronique Acid to STERéotaxique Radiotherapy in the Treatment of Vertebral Metastases Phase 3
Recruiting NCT05467540 - SPINERY™ A Novel Radio-Frequency Tumor Ablation Device Study N/A
Terminated NCT01527292 - Phase II Trial of Stereotactic Radiation Therapy (SRT) Versus SRT Plus Vertebral Augmentation Procedure (VAP) for Vertebral Metastasis N/A
Terminated NCT01654068 - Conformal High Dose Intensity Modulated Radiation Therapy for Disease to Thoracic and Lumbar Spine N/A